The Bulletin
Times Advertising


.

Kangpu Biopharmaceuticals to Present Results from Phase 2a of KPG-818 in SLE at EULAR 2024

  • Written by PR Newswire
Kangpu Biopharmaceuticals to Present Results from Phase 2a of KPG-818 in SLE at EULAR 2024

HEFEI, China, June 10, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals today announced that a poster tour presentation highlighting the Phase 2a clinical data of KPG-818 in patients with Systemic Lupus Erythematosus (SLE) will be presented at the upcoming Annual European Congress of Rheumatology EULAR 2024, taking place in Vienna, Austria, June...

hacklink hack forum hacklink film izle hacklink betturkeydepo 5ksahabetroyalbet girişslogan bahis resmiRocket Playcasibomiptv satın aliptv satın alcasibomtaraftarium24casibomjojobetholiganbet 1236holiganbetmarsbahis